At 19.4% CAGR, Asia Pacific Noninvasive Fat Reduction Market is Projected to be Worth US$ 1,709.85 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific noninvasive fat reduction market was valued at US$ 415.08 million in 2023 and is anticipated to reach US$ 1,709.85 million by 2031, recording a CAGR of 19.4% from 2023 to 2031. Growing adoption of noninvasive fat reduction procedures and product approvals and innovations are among the critical factors attributed to drive the Asia Pacific noninvasive fat reduction market growth.

According to The American Board of Cosmetic Surgery report, noninvasive fat reduction procedures are usually conducted within 90 minutes and results can be expected typically within 2 to 3 months. These procedures require less post-operative recovery time and do not cause scarring. Further, the mild redness at treatment sites subsides within a few hours or some days.

Source: THE AMERICAN BOARD OF COSMETIC SURGERY

The average cost of non-surgical fat reduction is approx. US$ 1,226, as per the statistics published in the American Society of Plastic Surgeons report. The average cost refers only to the consultation fees of the physician and doesn't include other noninvasive fat reduction procedure-related expenses. Other noninvasive fat reduction procedure expenses include procedure cost, time and effort of the treatment, and clinics/hospital geography locations.

Comparison Table of Surgical and Non-Surgical Fat Reduction Cost

Source: American Society of Plastic Surgeons

Therefore, the above table indicates that the surgical fat reduction option is more expensive than non-surgical fat reduction.

Furthermore, patients undergoing noninvasive fat reduction procedures can benefit more in terms of treatment time as compared with the surgical option.

Treatment Time for Each Noninvasive Fat Reduction Procedure

Source: American Academy of Dermatology Association

On the contrary, complications associated with noninvasive fat reduction procedures hamper the growth of Asia Pacific noninvasive fat reduction market.

Based on technology, the Asia Pacific noninvasive fat reduction market is bifurcated into cryolipolysis, laser lipolysis, ultrasound, and others. The cryolipolysis segment held 54.8% market share in 2023, amassing US$ 227.46 million. It is projected to garner US$ 1,084.21 million by 2031 to register 21.6% CAGR during 2023–2031.

By end users, the Asia Pacific noninvasive fat reduction market is divided into hospitals, dermatology clinics & cosmetic clinics, and others. The dermatology clinics & cosmetic clinics segment held 67.2% share of Asia Pacific noninvasive fat reduction market in 2023, amassing US$ 278.73 million. It is projected to garner US$ 1,215.02 million by 2031 to expand at 20.2% CAGR from 2023 to 2031.

Based on country, the Asia Pacific noninvasive fat reduction market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.7% share of Asia Pacific noninvasive fat reduction market in 2023. It was assessed at US$ 127.31 million in 2023 and is likely to hit US$ 609.11 million by 2031, registering a CAGR of 21.6% during 2023–2031.

Key players operating in the Asia Pacific noninvasive fat reduction market are Cynosure LLC Lumenis, Alma Lasers Ltd, Cutera Inc, Fotona, Sciton Inc, Venus Concept Inc, and Candela Corporation, among others.

• In August 2020, Lumenis announced launching of a new product "NuEra Tight" with Focal RF technology and this platform is a breakthrough in personalized noninvasive RF body treatments that meets patients unique needs. NuEra Tight with FocalRF technology is developed to provide tailor body treatments that meets patient's distinctive needs providing practitioners advanced tools for aesthetic patients accounting clinical indications and specific body areas all in one device.
• In July 2020, Venus Concept Inc. received FDA 510(k) clearance to market and sell Venus Viva MD. Venus Viva MD is a noninvasive device intended to be used by aesthetic-related physicians/dermatologists. It expands the Company’s skin rejuvenation offerings beyond the Venus Viva and Venus Versa which were introduced to the medical aesthetics market in 2015 and 2016, respectively.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com